Team
A Phase IIa trial with the new formulation of the hair loss treatment FOL-005 is expected to start in the…
Both the Q3 2019 revenues and result fell short of our expectations. But a divestment of the subsidiary…
Cantargia presents very promising early data from the ongoing Phase IIa trial in lung and pancreatic…
Adjusted for a goodwill amortization of SEKm 40 the EBIT reported by Consilium was slightly better than…
While Ecoclimes revenues in Q3/2019 came in somewhat lower than expected, the result was slightly better…
Amasten reported a very strong profit of SEKm 408 in Q3 2019. The result was to some 90 per cent made up…
ExpreS2ion provides a platform for the production of protein suited for next-generation vaccines,…
Flowscape experiences a strong order flow from large Corporate clients. More encouraging is that the…
Precise Biometrics (PB) reached higher than anticipated revenues of SEKm 27 out of which SEKm 17 came…
Aspire continues to deliver strong growth. Profitability was under pressure under the third quarter, but…
Verisecs report for the third quarter was mainly in line with our expectations. There were many positive…
Following additional property value gains, the Fastator stock is now priced without any NAV discount. We…